No Data
No Data
Zhicheng exclusive | Buying Hong Kong stocks in the south, how did Mainland active management public funds perform in the first half of the year?
With the disclosure of the performance report of mainland public funds investing in the Hong Kong and Shenzhen stock markets in the second quarter, investors can explore the situation of investing in Hong Kong stocks through the Hong Kong Stock Connect channel.
Hong Kong Stock Market Changes | Hygeia Health (06078) is up more than 4% now, new acquisition of hospital contributes to performance. Nomura expects to achieve record high first-half results.
Hygeia Health (06078) has risen over 4% and as of press time, it rose 3.58% to HK$27.5 with a turnover of HK$17.4431 million.
Nomura Adjusts Hygeia Healthcare's Price Target to HK$50.70 From HK$58.20, Keeps at Buy
Nomura: Maintains a 'buy' rating for Hygeia Health (06078) and lowers the target price to HKD 50.7.
Nomura has lowered its revenue forecasts for Hygeia Health for the next two years by 3.3% and 5.5% respectively.
The Recent 3.3% Gain Must Have Brightened CEO Yiwen Zhu's Week, Hygeia Healthcare Holdings Co., Limited's (HKG:6078) Most Bullish Insider
Soochow Securities: "Implementation Plan for Supporting the Development of Innovative Drugs Across the Entire Chain" Approved, and the innovative drugs sector is expected to strengthen.
Soochow Securities released research reports stating that the specific provisions of the "Implementation Plan for Full-chain Support of Innovative Drug Development" are expected to be implemented soon. In addition, the innovative drug sector is currently at a historically relatively low level. In the second half of the year, there will be multiple catalysts such as the ESMO conference, WCLC conference, medical insurance negotiations, and expectations for the innovative drug sector going global, which may lead to a strong performance in the innovative drug sector.
No Data